InvestorsHub Logo
Post# of 252455
Next 10
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

Re: None

Thursday, 10/18/2012 9:45:49 AM

Thursday, October 18, 2012 9:45:49 AM

Post# of 252455
Reata Pharmaceuticals has told Abbott Labs (ABT -4.4%) that it's discontinuing Phase 3 trials of bardoxolone methyl in patients with advanced chronic kidney disease and Type 2 diabetes following "excess serious adverse events and mortality." Reata and Abbott, which holds the rights to the drug outside the U.S., will examine the data to see whether it can still be developed. (8-K) [

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.